Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

• Main Authors: Dranoff, Glenn (Author), Kwan, Byron Hua (Contributor), Zhu, Eric Franklin (Contributor), Tzeng, Alice (Contributor), Sugito, Harun R. (Contributor), Eltahir, Ahmed A. (Contributor), Ma, Botong (Contributor), Delaney, Mary K. (Contributor), Murphy, Patrick A. (Contributor), Kauke, Monique Jacqueline (Contributor), Angelini, Alessandro (Contributor), Momin, Noor (Contributor), Mehta, Naveen (Contributor), Maragh, Alecia M. (Contributor), Hynes, Richard O. (Contributor), Cochran, Jennifer R. (Contributor), Wittrup, Karl Dane (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Department of Mathematics (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
• Format: Article
• Language: English
• Published: Rockefeller University Press, 2018-04-06T15:16:04Z.
• Subjects: Article
• Online Access: Get fulltext

 Certain RGD-binding integrins are required for cell adhesion, migration, and proliferation and are overexpressed in most tumors, making them attractive therapeutic targets. However, multiple integrin antagonist drug candidates have failed to show efficacy in cancer clinical trials. In this work, we instead exploit these integrins as a target for antibody Fc effector functions in the context of cancer immunotherapy. By combining administration of an engineered mouse serum albumin/IL-2 fusion with an Fc fusion to an integrin-binding peptide (2.5F-Fc), significant survival improvements are achieved in three syngeneic mouse tumor models, including complete responses with protective immunity. Functional integrin antagonism does not contribute significantly to efficacy; rather, this therapy recruits both an innate and adaptive immune response, as deficiencies in either arm result in reduced tumor control. Administration of this integrin-targeted immunotherapy together with an anti-PD-1 antibody further improves responses and predominantly results in cures. Overall, this well-tolerated therapy achieves tumor specificity by redirecting inflammation to a functional target fundamental to tumorigenic processes but expressed at significantly lower levels in healthy tissues, and it shows promise for translation.